Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
Rhea-AI Summary
Alterity Therapeutics (NASDAQ: ATHE) announced that CEO Dr. David Stamler will participate in the Bell Potter Healthcare Horizons Summit on 12-13 March 2026 in Sorrento, Australia.
Dr. Stamler will join a fireside chat titled “Optimising Late-stage Clinical Trials to Increase the Odds” and will hold 1-on-1 investor meetings.
Positive
- None.
Negative
- None.
News Market Reaction – ATHE
In the Mar 9 session, ATHE gained 3.50%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Leadership appointment | Positive | +0.0% | Appointment of Chief Medical Advisor to help advance ATH434 toward Phase 3. |
| Mar 02 | Awareness initiative | Positive | +0.3% | MSA Awareness Month outreach highlighting positive Phase 2 ATH434 data and development. |
| Jan 30 | Quarterly cash report | Neutral | -2.8% | Q2 FY26 cash flow update with A$49.2M cash and increased R&D spending. |
| Jan 21 | Shareholder letter | Positive | -1.5% | Shareholder letter detailing favourable Phase 2 ATH434 results and $2.4B MSA market. |
| Nov 12 | Conference participation | Neutral | +3.3% | CEO corporate update at Bell Potter Healthcare Virtual Conference for investors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically focused and strategic updates often saw modest or even negative price reactions, while prior conference participation produced a small positive move.
This announcement fits a pattern of ongoing visibility and late-stage development work for ATH434. Recent news includes a new Chief Medical Advisor on Mar 04, 2026, recognition of MSA Awareness Month with positive Phase 2 data on Mar 02, 2026, and a Q2 FY26 cash flow update showing A$49.2 million in cash and A$5.28 million operating outflows. Earlier, a 2025 shareholder letter highlighted "resoundingly favourable" Phase 2 results and an estimated $2.4 billion MSA market. A prior Bell Potter conference appearance in Nov 2025 led to a modest positive price reaction.
Key Terms
late-stage clinical trials medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia.
At the conference, Dr. Stamler will participate in a fireside chat entitled, “Optimising Late-stage Clinical Trials to Increase the Odds,” and will also host 1-on-1 investor meetings.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors:
Tara Speranza
Head of Investor Relations and Communications
tsperanza@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
